Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Earnings Massively Beat Expectations as Multiple Banks Raise Target Prices

Market Focus08-10

On August 10, BEONE MEDICINES rose 3.05% in regular trading, trading at 216.4 HKD/share, with turnover of 3.95 billion HKD.

On the news front, the company reported Q2 global revenue of $17.05 billion, up 30% year-over-year, with adjusted EPS of $3.84 significantly exceeding the consensus estimate of $1.44 by 167%. First-half net profit attributable to shareholders reached RMB 32.71 billion, surging 627.1% year-over-year. The company simultaneously raised its full-year revenue guidance to RMB 449-462 billion, driven by the leading position of its core product Brukinsa in the US market and continued expansion in Europe.

Multiple institutions upgraded their target prices following the results. CLSA raised its target to 321.7 HKD, CICC to 266 HKD, Bank of America to 255.43 HKD, and DBS to 265 HKD, all maintaining buy or outperform ratings. CMBI noted strong revenue growth, improving profitability, and rich R&D catalysts will continue to support valuation upside.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133528589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133528589","market":"us","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Earnings Massively Beat Expectations as Multiple Banks Raise Target Prices","media":"Market Focus","content":"<p><p>On August 10, BEONE MEDICINES rose 3.05% in regular trading, trading at 216.4 HKD/share, with turnover of 3.95 billion HKD.</p><p>On the news front, the company reported Q2 global revenue of $17.05 billion, up 30% year-over-year, with adjusted EPS of $3.84 significantly exceeding the consensus estimate of $1.44 by 167%. First-half net profit attributable to shareholders reached RMB 32.71 billion, surging 627.1% year-over-year. The company simultaneously raised its full-year revenue guidance to RMB 449-462 billion, driven by the leading position of its core product Brukinsa in the US market and continued expansion in Europe.</p><p>Multiple institutions upgraded their target prices following the results. CLSA raised its target to 321.7 HKD, CICC to 266 HKD, Bank of America to 255.43 HKD, and DBS to 265 HKD, all maintaining buy or outperform ratings. CMBI noted strong revenue growth, improving profitability, and rich R&D catalysts will continue to support valuation upside.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Earnings Massively Beat Expectations as Multiple Banks Raise Target Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Rises 3.05% in Regular Trading, Q2 Earnings Massively Beat Expectations as Multiple Banks Raise Target Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, BEONE MEDICINES rose 3.05% in regular trading, trading at 216.4 HKD/share, with turnover of 3.95 billion HKD.</p><p>On the news front, the company reported Q2 global revenue of $17.05 billion, up 30% year-over-year, with adjusted EPS of $3.84 significantly exceeding the consensus estimate of $1.44 by 167%. First-half net profit attributable to shareholders reached RMB 32.71 billion, surging 627.1% year-over-year. The company simultaneously raised its full-year revenue guidance to RMB 449-462 billion, driven by the leading position of its core product Brukinsa in the US market and continued expansion in Europe.</p><p>Multiple institutions upgraded their target prices following the results. CLSA raised its target to 321.7 HKD, CICC to 266 HKD, Bank of America to 255.43 HKD, and DBS to 265 HKD, all maintaining buy or outperform ratings. CMBI noted strong revenue growth, improving profitability, and rich R&D catalysts will continue to support valuation upside.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1133528589","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133528589","pubTimestamp":1786326674,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, BEONE MEDICINES rose 3.05% in regular trading, trading at 216.4 HKD/share, with turnover of 3.95 billion HKD.On the news front, the company reported Q2 global revenue of $17.05 billion,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势警报|BEONE MEDICINES 常规交易上涨 3.05%，多家银行上调目标价，第二季度盈利大幅超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On August 10, BEONE MEDICINES rose 3.05% in regular trading, trading at 216.4 HKD/share, with turnover of 3.95 billion HKD.On the news front, the company reported Q2 global revenue of $17.05 billion, up 30% year-over-year, with adjusted EPS of $3.84 significantly exceeding the consensus estimate of $1.44 by 167%. First-half net profit attributable to shareholders reached RMB 32.71 billion, surging 627.1% year-over-year. The company simultaneously raised its full-year revenue guidance to RMB 449-462 billion, driven by the leading position of its core product Brukinsa in the US market and continued expansion in Europe.Multiple institutions upgraded their target prices following the results. CLSA raised its target to 321.7 HKD, CICC to 266 HKD, Bank of America to 255.43 HKD, and DBS to 265 HKD, all maintaining buy or outperform ratings. CMBI noted strong revenue growth, improving profitability, and rich R&D catalysts will continue to support valuation upside.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133528589","isCrawlerRequest":true}